ImmunoGen Inc. (NASDAQ:IMGN) went up by 10.51% from its latest closing price compared to the recent 1-year high of $7.77. The company’s stock price has collected 30.16% of gains in the last five trading sessions. The Wall Street Journal reported on 02/15/22 that Virgin Galactic, Tower Semiconductor, CrowdStrike, Bitcoin: What to Watch in the Stock Market Today
Is It Worth Investing in ImmunoGen Inc. (NASDAQ :IMGN) Right Now?
Plus, the 36-month beta value for IMGN is at 1.16. Opinions of the stock are interesting as 7 analysts out of 10 who provided ratings for ImmunoGen Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $11.50, which is $7.9 above the current price. IMGN currently public float of 219.58M and currently shorts hold a 7.25% ratio of that float. Today, the average trading volume of IMGN was 4.23M shares.
IMGN’s Market Performance
IMGN stocks went up by 30.16% for the week, with a monthly jump of 16.15% and a quarterly performance of -4.65%, while its annual performance rate touched -37.40%. The volatility ratio for the week stands at 9.00% while the volatility levels for the past 30 days are set at 8.11% for ImmunoGen Inc. The simple moving average for the period of the last 20 days is 14.16% for IMGN stocks with a simple moving average of -24.93% for the last 200 days.
Analysts’ Opinion of IMGN
Many brokerage firms have already submitted their reports for IMGN stocks, with RBC Capital Mkts repeating the rating for IMGN by listing it as a “Sector Perform.” The predicted price for IMGN in the upcoming period, according to RBC Capital Mkts is $6 based on the research report published on March 21st of the current year 2022.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see IMGN reach a price target of $18. The rating they have provided for IMGN stocks is “Outperform” according to the report published on February 11th, 2022.
Jefferies gave a rating of “Buy” to IMGN, setting the target price at $12 in the report published on December 01st of the previous year.
IMGN Trading at -3.84% from the 50-Day Moving Average
After a stumble in the market that brought IMGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.23% of loss for the given period.
Volatility was left at 8.11%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares surge +14.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.82% lower at present.
During the last 5 trading sessions, IMGN rose by +30.16%, which changed the moving average for the period of 200-days by -33.76% in comparison to the 20-day moving average, which settled at $3.62. In addition, ImmunoGen Inc. saw -44.74% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for IMGN
Current profitability levels for the company are sitting at:
- -174.80 for the present operating margin
- +97.11 for the gross margin
The net margin for ImmunoGen Inc. stands at -199.41. Equity return is now at value -66.60, with -32.20 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 4.95.